Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 39 of 751 for:    Anti-Infective Agents AND Antibiotics, Antitubercular AND culture

Errors in Prescription Antibiotics in Ventilator-associated Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02074033
Recruitment Status : Unknown
Verified March 2014 by Ana Carolina Souza Oliveira, Federal University of Uberlandia.
Recruitment status was:  Recruiting
First Posted : February 28, 2014
Last Update Posted : March 27, 2014
Sponsor:
Information provided by (Responsible Party):
Ana Carolina Souza Oliveira, Federal University of Uberlandia

Brief Summary:
The infection is a major risk to hospitalized patients, especially those admitted to the Intensive Care Unit (ICU) and an unfavorable factor in the outcome of critically ill patients, increasing costs and prolonging hospitalization hospitalar. The ventilator-associated pneumonia (PAV) is considered the most prevalent nosocomial infection in the ICU, occurring in 9% to 68% of patients with prosthetic ventilatória.Due to the high rate of PAV and mortality related to it, is very important both prescription and administration of antibiotics correctly, as deescalation or escalation according the result of cultures.Therefore, the objectives of this study is assess if whether the antibiotic prescribed of ventilator-associated pneumonia following the orientation of literature. Will also be assessed the rate of PAV in patients critically ill adults, the main microorganisms responsible by PAV and determining antimicrobial susceptibility.

Condition or disease
Pneumonia

Detailed Description:

In patients who had a diagnosis of ventilator-associated pneumonia by asssistente physician will be assessed initially prescribed antibiotics empirically and what conduct adopted after culture results.

We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed ) . The deescalation consists of discontinuing the use of antimicrobial or antibiotic change to another with lower coverage and spectrum is performed, escalation occurs when adding a new antibiotic or antibiotic to change the coverage of other larger spectrum after culture results .


Layout table for study information
Study Type : Observational
Estimated Enrollment : 130 participants
Time Perspective: Retrospective
Official Title: Determination of Errors in Prescription Antibiotics in Ventilator-associated Pneumonia in Unit of Intensive Care of Clinical Hospital of Federal University of Uberlandia - Brazil
Study Start Date : March 2014
Estimated Primary Completion Date : April 2014
Estimated Study Completion Date : October 2014

Resource links provided by the National Library of Medicine


Group/Cohort
antibiotics for pneumonia
We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed )



Primary Outcome Measures :
  1. Determination of Errors in Prescription Antibiotics in Ventilator-associated Pneumonia in Unit of Intensive Care of Clinical Hospital of Federal University of Uberlandia - Brazil [ Time Frame: six months ]

Biospecimen Description:
No samples will be retained for the study


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study is a retrospective study to evaluate the use of antibiotics in the ventilator-associated pneumonia (PAV) in the Intensive Care Unit of the Adult Clinical Hospital of the Federal University of Uberlândia. The UnitAdult Intensive Care has complexity level III and consists of 30 beds.O number of statistically significant sample is 130 patients.
Criteria

Inclusion Criteria:

  • Be 18 years of age;
  • Having the diagnosis of ventilator-associated pneumonia.

Exclusion Criteria:

  • Be under 18 years of age;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02074033


Contacts
Layout table for location contacts
Contact: Ana Carolina Souza Oliveira 055343182150 acsouzao@yahoo.com.br

Locations
Layout table for location information
Brazil
Ana Carolina Souza Oliveira Recruiting
Uberlândia, Minas Gerais, Brazil, 38405322
Principal Investigator: Denise Von Dollinger de Brito         
Principal Investigator: Ana Carolina Souza Oliveira         
Principal Investigator: Thúlio Marquez Cunha         
Principal Investigator: Fabiola Alves Gomes         
Sponsors and Collaborators
Federal University of Uberlandia
Investigators
Layout table for investigator information
Principal Investigator: Ana Carolina Souza Oliveira Federal University of Uberlandia
Principal Investigator: Denise Von Dollinger de Brito Federal University of Uberlandia
Principal Investigator: Thúlio Marquez Cunha Federal University of Uberlandia
Principal Investigator: Fabiola Alves Gomes Federal University of Uberlandia

Additional Information:
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, New  This link exits the ClinicalTrials.gov site ALVAREZ-LERMA, F. et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: A prospective observational study. Crit Care, London, v.10, n.3, p.1-11, May 2006.  This link exits the ClinicalTrials.gov site ANGUS, D.C.et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associa¬ted costs of care. Crit Care Med, New York, v.29, n.7, p.1303-1310, Jul 2001.  This link exits the ClinicalTrials.gov site BURKE, J.P. Infection control- a problem for patient safety. N Engl J Med, Melbourn, v.348, n.7, p. 651-656, Feb 2003.  This link exits the ClinicalTrials.gov site CAMARGO, L. F. A. et al. Ventilator associated pneumonia: comparison between quantitative and qualitative cultures of tracheal aspirates. Critical Care Medicine, New York, v.8, n.6, p. 422-430, Dec 2004.  This link exits the ClinicalTrials.gov site EACHEMPATI, S.R. et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma, Baltimore, v.66, n.5, p.1343-1348, May 2009.  This link exits the ClinicalTrials.gov site ERBAY, A., BODUR, H., AKINCI, E., ÇOLPAN, A. Evaluation of antibiotic use in intensive care units of a tertiary care hospital in Turkey. Journal of Hospital Infection, New York , v.59, p.53-61, Jan 2005.  This link exits the ClinicalTrials.gov site GOMES SILVA, B.N. et al. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev, Oxford,v.8, n.12, CD007934, Dec 2010.  This link exits the ClinicalTrials.gov site HEENEN, S., JACOBS, F., VINCENT,J-P. Antibiotic strategies in severe nosocomial sepsis: Why do we not de-escalate more often? Crit Care Med, New York, v.40, n.5, p.1404-1409, May 2012 .  This link exits the ClinicalTrials.gov site RELLO, J. et al. De-escalation therapy in ventilator associated pneumonia. Crit Care Med , New York, v.32, n.11, p.2183-2190, Nov 2004.  This link exits the ClinicalTrials.gov site SAFDAR, N.; CRNICH, C.J.; MAKI, D.G. The Pathogenesis of Ventilator-Associated Pneumonia: Its Relevance to Developing Effective Strategies for Prevention. Respiratory Care, Philadelphia, v.50, n.6, p.725-739, Jun 2005.  This link exits the ClinicalTrials.gov site WAELE, J.J.D.et al. De-escalation after empirical meropenem treatment in the intensive care unit: Fiction or reality? Journal of Critical Care, Orlando, v.25, n.4, p.641-646, Jan 2010.  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Ana Carolina Souza Oliveira, graduate student, Federal University of Uberlandia
ClinicalTrials.gov Identifier: NCT02074033     History of Changes
Other Study ID Numbers: 30121978
First Posted: February 28, 2014    Key Record Dates
Last Update Posted: March 27, 2014
Last Verified: March 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents
Pneumonia, Ventilator-Associated
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection
Infection